Expression of Cytochrome P 450 1 B 1 and Catechol-O-Methyltransferase in Breast Tissue and Their Associations with Breast Cancer Risk

Cytochrome P450 1B1 (CYP1B1) and catechol-O-methyltransferase (COMT) are important estrogen-metabolizing enzymes that may affect breast cancer risk. Few studies have directly measured the expression of CYP1B1 and COMT genes in breast tissue samples. The subjects in this study were a subgroup of participants of the Shanghai Breast Cancer Study including 64 patients diagnosed with breast cancer and 68 patients diagnosed with benign breast diseases (BBD) who provided samples of tumor tissue and adjacent nontumor tissue to the study. We compared CYP1B1 and COMT mRNA expression in tumor tissue and adjacent nontumor tissue in both breast cancer patients and BBD patients. High levels of CYP1B1 expression and low levels of COMT expression in adjacent nontumor tissue were associated with a significantly increased breast cancer risk in a nonlinear manner. Odds ratios and 95% confidence intervals (in parentheses) for the midpoints of the first, second, fourth, and fifth quintiles of gene expression levels compared with the overall median levels in BBD subjects were 0.21 (0.07-0.67), 0.81 (0.69-0.95), 1.20 (1.05-1.38), and 1.55 (1.12-2.15) for CYP1B1 and 1.72 (1.172.55), 1.19 (1.05-1.35), 0.83 (0.73-0.95), and 0.78 (0.65-0.93) for COMT, respectively. These results support the hypothesis that the formation and accumulation of catechol estrogens in breast tissue through increased CYP1B1 expression and reduced COMT expression may play a significant role in breast cancer risk. (Cancer Epidemiol Biomarkers Prev 2007;16(5):917–20)

[1]  Perry J. Johnson,et al.  Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. , 2005, Oncology reports.

[2]  R. Dahiya,et al.  Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer , 2005, Clinical Cancer Research.

[3]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[4]  X. Shu,et al.  Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis , 2005, Cancer Epidemiology Biomarkers & Prevention.

[5]  A. Whittemore,et al.  A Family-based Genetic Association Study of Variants in Estrogen-metabolism Genes COMT and CYP1B1 and Breast Cancer Risk , 2004, Breast Cancer Research and Treatment.

[6]  Hue Lee,et al.  Increased expression of cytochrome P4501B1 in peripheral leukocytes from lung cancer patients. , 2004, Toxicology letters.

[7]  A. Folsom,et al.  CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. , 2004, Cancer letters.

[8]  Francesmary Modugno,et al.  A Potential Role for the Estrogen-metabolizing Cytochrome P450 Enzymes in Human Breast Carcinogenesis , 2003, Breast Cancer Research and Treatment.

[9]  M. Denison,et al.  Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. , 2003, Annual review of pharmacology and toxicology.

[10]  K. Humphreys,et al.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. , 2003, Carcinogenesis.

[11]  E. Weiderpass,et al.  Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. , 2003, Carcinogenesis.

[12]  A. Daly,et al.  Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population , 2002, Archives of Toxicology.

[13]  O. Pelkonen,et al.  The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue , 2001, Breast Cancer Research and Treatment.

[14]  D. Noh,et al.  Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. , 2001, Pharmacogenetics.

[15]  T. Sellers,et al.  Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study , 2000, International journal of cancer.

[16]  P Royston,et al.  The use of fractional polynomials to model continuous risk variables in epidemiology. , 1999, International journal of epidemiology.

[17]  D. Henson,et al.  Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.

[18]  N. Walker,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Royston,et al.  Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. , 1994 .

[21]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[22]  C. Marsden,et al.  Catechol-O-methyl transferase: pharmacological aspects and physiological role. , 1975, Pharmacological reviews.

[23]  P. Royston,et al.  Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials , 1999 .